Urodynamic study and its correlation with cardiac meta-iodobenzylguanidine (MIBG) in body-first and brain-first subtypes of Parkinson's disease.
Parkinson's disease
REM sleep behavior disorder
cardiac MIBG scintigraphy
lower urinary tract symptoms
overactive bladder
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
revised:
21
08
2024
received:
16
06
2024
accepted:
12
09
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Lower urinary tract symptoms (LUTS) are frequently observed in patients with Parkinson's disease (PD), but the underlying mechanism remains elusive. The concept of "body-first" and "brain-first" subtypes in PD has been proposed, but the correlation of PD subtype with LUTS remains unclear. We aimed to investigate the disparities in urological dysfunctions between body-first and brain-first subtypes of PD using urodynamic studies (UDS). We reviewed patients with PD (disease duration <3 years) who had undergone UDS and completed urological questionnaires (Overactive Bladder Symptom Score [OABSS] and International Prostate Symptom Score [IPSS]) and a voiding diary. Patients were categorized as having body-first or brain-first PD based on cardiac sympathetic denervation (CSD) using cardiac meta-iodobenzylguanidine (MIBG) uptake and the presence of rapid eye movement sleep behavior disorder (RBD), assessed using a questionnaire (PD with CSD and RBD indicating the body-first subtype). A total of 55 patients with PD were categorized into body-first PD (n = 37) and brain-first PD (n = 18) groups. The body-first PD group exhibited smaller voiding volume and first desire volume (FDV) than the brain-first PD group (p < 0.05 in both). Also, the body-first PD group had higher OABSS and IPSS scores, and higher prevalence of overactive bladder diagnosed by OABSS, compared to the brain-first PD group. In multiple linear regression, cardiac MIBG uptake was positively correlated with FDV and voiding volume and negatively correlated with OABSS and IPSS (p < 0.05 in all). Patients with the body-first PD subtype exhibited more pronounced overactive bladder symptoms and impaired storage function in the early stage of disease. Additionally, cardiac MIBG was significantly associated with urological dysfunction.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Lower urinary tract symptoms (LUTS) are frequently observed in patients with Parkinson's disease (PD), but the underlying mechanism remains elusive. The concept of "body-first" and "brain-first" subtypes in PD has been proposed, but the correlation of PD subtype with LUTS remains unclear. We aimed to investigate the disparities in urological dysfunctions between body-first and brain-first subtypes of PD using urodynamic studies (UDS).
METHODS
METHODS
We reviewed patients with PD (disease duration <3 years) who had undergone UDS and completed urological questionnaires (Overactive Bladder Symptom Score [OABSS] and International Prostate Symptom Score [IPSS]) and a voiding diary. Patients were categorized as having body-first or brain-first PD based on cardiac sympathetic denervation (CSD) using cardiac meta-iodobenzylguanidine (MIBG) uptake and the presence of rapid eye movement sleep behavior disorder (RBD), assessed using a questionnaire (PD with CSD and RBD indicating the body-first subtype).
RESULTS
RESULTS
A total of 55 patients with PD were categorized into body-first PD (n = 37) and brain-first PD (n = 18) groups. The body-first PD group exhibited smaller voiding volume and first desire volume (FDV) than the brain-first PD group (p < 0.05 in both). Also, the body-first PD group had higher OABSS and IPSS scores, and higher prevalence of overactive bladder diagnosed by OABSS, compared to the brain-first PD group. In multiple linear regression, cardiac MIBG uptake was positively correlated with FDV and voiding volume and negatively correlated with OABSS and IPSS (p < 0.05 in all).
CONCLUSIONS
CONCLUSIONS
Patients with the body-first PD subtype exhibited more pronounced overactive bladder symptoms and impaired storage function in the early stage of disease. Additionally, cardiac MIBG was significantly associated with urological dysfunction.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16497Subventions
Organisme : National Research Foundation
ID : 2022R1A2C2091254
Organisme : National Research Foundation
ID : RS-2023-00246655
Organisme : Ministry of Health and Welfare
ID : RS-2023-00265159
Organisme : Ministry of Health and Welfare
ID : RS-2023-00266948
Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8‐16.
Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire‐based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci. 2001;92(1–2):76‐85.
Liu Z, Uchiyama T, Sakakibara R, Yamamoto T. Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease. Int Urol Nephrol. 2015;47(5):751‐757.
Kitta T, Kakizaki H, Furuno T, et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. J Urol. 2006;175(3 Pt 1):994‐998.
Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [(123)I]‐beta‐CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci. 2001;187(1–2):55‐59.
Borghammer P, Horsager J, Andersen K, et al. Neuropathological evidence of body‐first vs. brain‐first Lewy body disease. Neurobiol Dis. 2021;161:105557.
Horsager J, Andersen KB, Knudsen K, et al. Brain‐first versus body‐first Parkinson's disease: a multimodal imaging case‐control study. Brain. 2020;143(10):3077‐3088.
Borghammer P, Van Den Berge N. Brain‐first versus gut‐first Parkinson's disease: a hypothesis. J Parkinsons Dis. 2019;9(s2):S281‐S295.
Horsager J, Knudsen K, Sommerauer M. Clinical and imaging evidence of brain‐first and body‐first Parkinson's disease. Neurobiol Dis. 2022;164:105626.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745‐752.
Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37(6):1131‐1148.
Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol. 1996;3(4):261‐266.
Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68(2):318‐323.
Postuma RB, Arnulf I, Hogl B, et al. A single‐question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27(7):913‐916.
Chaudhuri KR, Martinez‐Martin P, Brown RG, et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord. 2007;22(13):1901‐1911.
Sawada H, Oeda T, Yamamoto K, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol. 2009;16(2):174‐182.
Ryu DW, Yoo SW, Oh YS, Lee KS, Ha S, Kim JS. Comparison of disease progression between brain‐predominant Parkinson's disease versus Parkinson's disease with body‐involvement phenotypes. Neurobiol Dis. 2022;174:105883.
Hattori T, Yasuda K, Kita K, Hirayama K. Voiding dysfunction in Parkinson's disease. Jpn J Psychiatry Neurol. 1992;46(1):181‐186.
Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry. 2000;68(4):429‐433.
Defreitas GA, Lemack GE, Zimmern PE, Dewey RB, Roehrborn CG, O'Suilleabhain PE. Distinguishing neurogenic from non‐neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease. Urology. 2003;62(4):651‐655.
Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276‐281.
Uchiyama T, Sakakibara R, Yamamoto T, et al. Urinary dysfunction in early and untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011;82(12):1382‐1386.
Pagano G, Niccolini F, Yousaf T, et al. Urinary dysfunction in early de novo patients with Parkinson's disease. Mov Disord. 2017;32(6):939‐940.
Zhuang H, Wang X, Xu H, Jing X, Yue J. Characteristics and risk factors of lower urinary tract dysfunction in patients with Parkinson's disease: a systematic evaluation and meta‐analysis. Clin Neurol Neurosurg. 2021;209:106885.
Wang J, Cao R, Huang T, Liu C, Fan Y. Urinary dysfunction is associated with nigrostriatal dopaminergic degeneration in early and untreated patients with Parkinson's disease. Parkinsons Dis. 2020;2020:4981647.
Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol. 2005;12(11):842‐850.
Askari A, Zhu BJ, Lam JL, Wyant KJ, Chou KL, Patil PG. Impact of subthalamic nucleus stimulation on urinary dysfunction and constipation in Parkinson's disease. J Neurosurg. 2023;140(3):657‐664.
Nazzaro JM, Pahwa R, Lyons KE. The impact of bilateral subthalamic stimulation on non‐motor symptoms of Parkinson's disease. Parkinsonism Relat Disord. 2011;17(8):606‐609.
Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22(2):220‐225.
Sumikura H, Takao M, Hatsuta H, et al. Distribution of alpha‐synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol Commun. 2015;3:57.
Matsubara T, Murayama S, Tsukamoto T, et al. Parkinson's disease in a patient with olfactory hypoplasia: a model case of “body‐first Lewy body disease” providing insights into the progression of alpha‐synuclein accumulation. J Neurol. 2023;270(10):5090‐5093.
VanderHorst VG, Samardzic T, Saper CB, et al. Alpha‐Synuclein pathology accumulates in sacral spinal visceral sensory pathways. Ann Neurol. 2015;78(1):142‐149.
Neikrug AB, Avanzino JA, Liu L, et al. Parkinson's disease and REM sleep behavior disorder result in increased non‐motor symptoms. Sleep Med. 2014;15(8):959‐966.
Romenets SR, Gagnon JF, Latreille V, et al. Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. Mov Disord. 2012;27(8):996‐1003.
Liu H, Ou R, Wei Q, et al. Rapid eye movement behavior disorder in drug‐naive patients with Parkinson's disease. J Clin Neurosci. 2019;59:254‐258.
Rolinski M, Szewczyk‐Krolikowski K, Tomlinson PR, et al. REM sleep behaviour disorder is associated with worse quality of life and other non‐motor features in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560‐566.
Pagano G, de Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91(10):e894‐e905.
Valentino F, Bartolotta TV, Cosentino G, et al. Urological dysfunctions in patients with Parkinson's disease: clues from clinical and non‐invasive urological assessment. BMC Neurol. 2018;18(1):148.
Erro R, Picillo M, Amboni M, et al. Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. Mov Disord. 2015;30(3):373‐378.
Halsband C, Zapf A, Sixel‐Döring F, Trenkwalder C, Mollenhauer B. The REM sleep behavior disorder screening questionnaire is not valid in de novo Parkinson's disease. Mov Disord Clin Pract. 2018;5(2):171‐176.
Stiasny‐Kolster K, Sixel‐Döring F, Trenkwalder C, et al. Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. Sleep Med. 2015;16(1):186‐189.
Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha‐synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain. 2008;131(Pt 3):642‐650.
Borghammer P. The brain‐first vs. body‐first model of Parkinson's disease with comparison to alternative models. J Neural Transm (Vienna). 2023;130(6):737‐753.
Tsukita K, Tachibana N, Hamano T. Appropriate assessment method of (123)I‐MIBG myocardial scintigraphy for the diagnosis of Lewy body diseases and idiopathic REM sleep behavior disorder. J Neurol. 2020;267(11):3248‐3257.
Nomura T, Inoue Y, Högl B, et al. Relationship between (123)I‐MIBG scintigrams and REM sleep behavior disorder in Parkinson's disease. Parkinsonism Relat Disord. 2010;16(10):683‐685.
Kashihara K, Imamura T, Shinya T. Cardiac 123I‐MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. Parkinsonism Relat Disord. 2010;16(4):252‐255.
Miyamoto T, Miyamoto M, Iwanami M, Hirata K. Cardiac 123I‐MIBG accumulation in Parkinson's disease differs in association with REM sleep behavior disorder. Parkinsonism Relat Disord. 2011;17(3):219‐220.